Keros Therapeutics, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Keros Therapeutics received a $20 million development milestone payment from Takeda following first patient dosing in the ELRiSE MDS Phase 3 trial for elritercept. This milestone is one tranche under the January 2025 global license agreement in which Keros received $200 million upfront and remains eligible for up to $1.1 billion in total milestones plus royalties. Keros plans to distribute 25% of the net cash proceeds ($5 million) to shareholders.
Why this rating
Milestone is 4.4% of company market cap (~$453M), confirming partnership progress. Routine for development-stage biotech; near-term cash benefit modest relative to $200M upfront already received in Feb 2025.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.